Zacks Research Has Bullish Forecast for AGIO FY2026 Earnings

Posted by Geri Gentry on Sep 22nd, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) – Analysts at Zacks Research boosted their FY2026 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research note issued on Thursday, September 17th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of ($6.93) per share for the year, up from their prior forecast of ($6.94). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.82) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.76) EPS, Q1 2027 earnings at ($1.59) EPS, Q2 2027 earnings at ($1.60) EPS, Q3 2027 earnings at ($1.49) EPS, Q4 2027 earnings at ($1.42) EPS, FY2027 earnings at ($6.11) EPS, Q1 2028 earnings at ($1.21) EPS, Q2 2028 earnings at ($1.01) EPS and FY2028 earnings at ($3.70) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The company had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%.

A number of other brokerages have also recently issued reports on AGIO. Bank of America boosted their price objective on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a report on Monday. HC Wainwright increased their target price on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Citigroup boosted their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, Truist Financial lowered their price objective on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating for the company in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Agios Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $41.75.

View Our Latest Stock Report on Agios Pharmaceuticals

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $33.95 on Monday. The stock has a market cap of $2.03 billion, a PE ratio of -4.84 and a beta of 0.60. The stock has a 50-day moving average of $34.28 and a 200-day moving average of $32.20. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently modified their holdings of the business. Sei Investments Co. boosted its holdings in shares of Agios Pharmaceuticals by 342.8% in the 1st quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $2,150,000 after buying an additional 49,198 shares during the last quarter. SCS Capital Management LLC acquired a new position in Agios Pharmaceuticals during the second quarter worth $22,743,000. Seven Fleet Capital Management LP bought a new stake in Agios Pharmaceuticals during the fourth quarter worth $864,000. GW&K Investment Management LLC raised its position in Agios Pharmaceuticals by 41.5% during the fourth quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock worth $32,863,000 after acquiring an additional 354,359 shares in the last quarter. Finally, Erste Asset Management GmbH raised its position in Agios Pharmaceuticals by 1.4% during the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after acquiring an additional 40,000 shares in the last quarter.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the sale, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. This trade represents a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

(Get Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases, with an emphasis on disorders involving cellular metabolism. The company’s research has centered on small-molecule therapies designed to address underlying biological mechanisms rather than only treating symptoms.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase approved in the United States and other markets for the treatment of hemolytic anemia associated with pyruvate kinase deficiency in adults.